BrainsWay Ltd.

Stage 4 · Declining · week 2

As of Oct 22, 2026, BrainsWay is in Stage 4, the downtrend phase, now in week 2 (since Oct 15, 2026). It closed at $11.44, 33.4% below its 52-week high and below its 200-day average, which is rising.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. More about the company

$11.44

-4.51% today

$460M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BWAY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 30w

S2 56w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 30w → S3 12w → S2 30w → S3 3w → S2 9w → S3 4w → S4 4w → S1 2w → S2 56w → S3 5w → S2 4w → S3 4w → S4 1w current

Total tracked: 166 weeks across 13 stage runs.

BWAY among Medical Devices21st of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…21	BWAYBrainsWay Ltd.	Stage 4 · wk 2	82	−14.9%

vs 52W High

-33.4%

$7.25 lo$17.17 hi

33.4% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-17.9%

200 DMA: $13.93 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.63x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.9%

-28.4%

-27.4%

YTD

+18.6%

+40.5%

Scan Membership

Breakout Watch

Latest: 2025-06-18

8 appearances in last 60 days. First seen: 2020-01-31.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.63x

2026-10-21S4

Wk 1 · Vol 0.34x

2026-10-20S4

Wk 1 · Vol 0.66x

2026-10-19S4

Wk 1 · Vol 0.98x

2026-10-16S4

Wk 1 · Vol 0.59x

2026-10-15S43→4

Wk 1 · Vol 0.98x

2026-10-14S3

Wk 5 · Vol 1.02x

2026-10-13S3

Wk 5 · Vol 1.35x

2026-10-12S3

Wk 4 · Vol 1.41x

2026-10-09S3

Wk 4 · Vol 0.93x

2026-10-08S3

Wk 4 · Vol 1.06x

2026-10-07S3

Wk 4 · Vol 1.18x

Moving averages & range

50 DMA

$13.44

200 DMA

$13.93

52W High

$17.17

52W Low

$7.25

5D Low

$11.44

Resistance levels (recent highs)

20d High

$13.48

60d High

$16.60

120d High

$17.17

250d High

$17.17

Next resistance

+17.8%

to 20d High

P/E (TTM)

49.7

Forward 22.6

Earnings Growth (YoY)

+59.8%

Revenue +35.4%

ROE

+12.8%

Profit margin +15.6%

Dividend Yield

0.00%

P/B 5.8

BrainsWay: quick answers

What stage is BrainsWay in?

As of Oct 22, 2026, BrainsWay (BWAY) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 15, 2026 and is in week 2. What the four stages mean

Is BrainsWay in an uptrend?

No. BrainsWay is in a Stage 4 downtrend. It trades 17.9% below its 200-day average, which is rising.

How far is BrainsWay from its 52-week high?

BrainsWay closed at $11.44 on Oct 22, 2026, 33.4% below its 52-week high of $17.17. Its 52-week low is $7.25.

How has BrainsWay performed over the past year?

As of Oct 22, 2026, BrainsWay is up 40.5% over the past year and up 18.6% so far in 2026.

Which sector and industry is BrainsWay in?

BrainsWay is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.